News | Heart Valve Technology | July 09, 2019

Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference

Clinical results show resolution of mitral regurgitation with Tiara TMVR device, reduction in angina severity with Reducer

Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference

July 9, 2019 — Neovasc Inc. announced that its Tiara transcatheter mitral valve replacement (TMVR) device and its Neovasc Reducer device for the treatment of refractory angina were highlighted in presentations at the CSI Frankfurt 2019 conference, June 26-29, in Frankfurt, Germany.

Lenard Conradi, M.D., surgical director of minimally invasive and transcatheter heart valve procedures, University Heart Center Hamburg, Department of Cardiovascular Surgery, provided an overview of the TIARA program, including in-depth imaging required for screening patients, and clinical evidence demonstrating the resolution of mitral regurgitation and improvement in New York Heart Association (NYHA) class. 

Tiara is a self-expanding mitral bioprosthesis specifically designed to treat mitral valve regurgitation (MR) by replacing the diseased valve. Conventional surgical treatments are only appropriate for about half of MR patients, who number an estimated 4 million in the U.S. with a similar number of patients affected throughout Europe. Tiara is implanted in the heart using a minimally invasive, transapical transcatheter approach without the need for open-heart surgery or use of a cardiac bypass machine.

Prof. Shmuel Banai, M.D., Neovasc's medical director, presented an overview of the Reducer's performance following more than 1,000 devices implanted in Europe. In the presentation evidence-based data was presented, demonstrating the high efficacy and safety profile of the Reducer in reducing angina severity, improving quality of life, improving exercise capacity, and improving systolic and diastolic function of the heart.

The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.

For more information: www.neovasc.com


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now